Cisplatin and c-myb Antisense Oligonucleotides in Colon Cancer
Author Information
Author(s): D Del Bufalo, C Cucco, C Leonetti, G Citro, I D'Agnano, M Benassi, T Geiser, G Zon, B Calabretta, G Zupi
Primary Institution: Regina Elena Institute for Cancer Research
Hypothesis
Can the combination of c-myb antisense phosphorothioate oligodeoxynucleotides and cisplatin improve treatment outcomes in colon cancer?
Conclusion
The combination of c-myb antisense oligodeoxynucleotides and cisplatin significantly inhibits tumor growth in colon cancer models.
Supporting Evidence
- Antisense treatment decreased c-myb mRNA and protein expression.
- Combination treatment resulted in greater tumor growth inhibition compared to individual treatments.
- Significant reduction in tumor weight was observed in treated mice.
Takeaway
This study shows that using a special type of medicine that targets cancer genes, along with a common cancer drug, can help shrink tumors in colon cancer.
Methodology
The study involved in vitro and in vivo experiments using the LoVo Dx colon carcinoma cell line, assessing the effects of c-myb antisense oligodeoxynucleotides and cisplatin on cell proliferation and tumor growth.
Limitations
The study primarily focuses on a single cell line and may not fully represent the complexity of colon cancer in humans.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website